PARIS and CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) — NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix"Or the"Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announces today the closing of the previously announced subscription by Johnson & Johnson Innovation – JJDC, Inc. (“JJDC”) for 901,256 additional ordinary shares of the Company, in the form of restricted American Depositary Shares (“ADSs”), for an aggregate amount of $4.8 million, equivalent to €4.6 million1 (the “Remaining Placement Amount", and the subscription transaction being the "Remaining Placement”), following the approval by the French Ministry of Economy of JJDC Remaining Placement on November 22, 2023, in accordance with the French foreign investment control rules2.
The naval sector is a true global economic power, which has navigated towards a 150 billion market...
Last Monday, the Financial Times announced a deal with OpenAI. FT licenses its world-class journalism…
Millions of people pay for streaming services, paying monthly subscription fees. It is common opinion that you…
Coveware by Veeam will continue to provide cyber extortion incident response services. Coveware will offer forensics and remediation capabilities…
